Literature DB >> 16761908

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Nick Bosanquet, Andrew Yeates.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16761908     DOI： 10.2165/00019053-200624060-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  11 in total

1.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.

Authors:  Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Cognitive disability and direct care costs for elderly people.

Authors:  S Kavanagh; M Knapp
Journal:  Br J Psychiatry       Date:  1999-06       Impact factor: 9.319

4.  Patterns and predictors of institutionalization in community-based dementia patients.

Authors:  M A Severson; G E Smith; E G Tangalos; R C Petersen; E Kokmen; R J Ivnik; E J Atkinson; L T Kurland
Journal:  J Am Geriatr Soc       Date:  1994-02       Impact factor: 5.562

5.  Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII.

Authors:  A Heyman; B Peterson; G Fillenbaum; C Pieper
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Authors:  R C Mohs; R S Doody; J C Morris; J R Ieni; S L Rogers; C A Perdomo; R D Pratt
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

7.  Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

Authors:  David S Geldmacher; George Provenzano; Thomas McRae; Vera Mastey; John R Ieni
Journal:  J Am Geriatr Soc       Date:  2003-07       Impact factor: 5.562

8.  Does diagnosis determine delivery? The Islington study of older people's needs and health care costs.

Authors:  T Nelson; J L Fernandez; G Livingston; M Knapp; C Katona
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

9.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

10.  Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Authors:  S Gauthier; H Feldman; J Hecker; B Vellas; B Emir; P Subbiah
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580
View more
  4 in total

1.  Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations.

Authors:  Richard J Phillips; Nick Bosanquet
Journal:  BMJ       Date:  2006-09-16

2.  Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Authors:  Denis Getsios; Steve Blume; K Jack Ishak; Grant D H Maclaine
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Authors:  Denis Getsios; Kristen Migliaccio-Walle; Jaime J Caro
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Authors:  Susanne Hartz; Denis Getsios; Sunning Tao; Steve Blume; Grant Maclaine
Journal:  BMC Neurol       Date:  2012-02-08       Impact factor: 2.474
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.